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Abstract
Objective: The study was designed to evaluate real-world data on clinical and economic outcome differences between
patients with type 2 diabetes mellitus (T2DM) who use insulin glargine with vial-and-syringe delivery and those who switch
to pen administration.
Subjects and Methods: This retrospective study analyzed medical and pharmacy claims information from the national
managed-care IMPACT database (Ingenix Inc., Salt Lake City, UT). Adults with T2DM treated with insulin glargine were
evaluated. Clinical and economic outcomes over 1 year were compared between individuals who had converted from
administering glargine via vial-and-syringe to the SoloSTAR (sanofi-aventis U.S., Bridgewater, NJ) pen (Switchers) and
patients who continued to use vial-and-syringe administration (Continuers). Patients from each cohort were matched using
propensity score matching for a comparison sample.
Results: In total, 3,893 eligible patients were identified (665 Switchers and 3,228 Continuers), with a matched cohort with 603
patients in each group. Baseline characteristics were similar between groups. One-year treatment persistence was signifi-
cantly higher with Switchers versus Continuers (65.3% vs. 49.8%; P < 0.0001). Medication possession ratio was also signifi-
cantly higher among Switchers (0.79 vs. 0.76; P = 0.0173). Insulin use and glycemic control were similar between groups.
Healthcare utilization and total costs were also similar between groups. Higher prescription costs among Switchers were
offset by lower overall and diabetes-related outpatient and inpatient costs.
Conclusions: Switching from insulin glargine vial-and-syringe administration to pen delivery resulted in improved treatment
adherence and persistence, with comparable clinical and economic outcomes.
Introduction
Basal insulin use is recommended in patients withtype 2 diabetes mellitus (T2DM) who are unable to
achieve adequate glycemic control despite the use of oral
antidiabetes drugs.1–3 Insulin has traditionally been admin-
istered using a syringe to extract insulin stored in a vial,1 but
the anxiety, fear of pain, and social embarrassment associated
with syringe-and-vial insulin may reduce insulin acceptance
and treatment adherence.4–7 Alternatively, insulin may be
delivered using prefilled disposable pen devices. Both pa-
tients and physicians prefer insulin pens because of enhanced
discretion, ease of use, and convenience of self-injection.1,4,8–10
Pen devices also improve patient confidence in drug admin-
istration and glycemic control, whichmay also facilitate better
adherence to insulin treatment.4
Several studies have investigated the delivery of insulin via
disposable pen devices compared with vial-and-syringe de-
livery.5,11–15 However, not many have studied the effect of
switching from vial-and-syringe delivery to disposable
pens.11,12 Those that have studied the effect of switching an-
alyzed treatment adherence, resource utilization, and associ-
ated healthcare costs but did not include glycosylated
hemoglobin (A1C) as an end point. Furthermore, they used a
time frame of July 2001–December 2002, which does not
capture the newer insulin pens, such as insulin glargine
SoloSTAR (sanofi-aventis U.S., Bridgewater, NJ). Therefore
more up-to-date studies are needed that include A1C as a
parameter of glycemic control and incorporate newer insulin
pen devices.
Evidence derived from studies in which patients initiate
therapy with an insulin glargine pen compared with insulin
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glargine vial-and-syringe cannot be readily applied to pa-
tients who switch from insulin glargine vial-and-syringe to
insulin glargine pens because the switchers are likely to have
different baseline characteristics and face different challenges
compared with initiators. Therefore, a study on clinical and
economic outcomes of patients switching from insulin glar-
gine vial-and-syringe to insulin glargine pens is required.
The current study aims to evaluate the real-world clinical
and economic outcomes among patients who were already
administering insulin glargine therapy via vial-and-syringe
who then switched to a prefilled disposable insulin glargine
pen device (SoloSTAR).
Subjects and Methods
This retrospective analysis evaluated data from the na-
tional managed-care IMPACT database (Ingenix Inc., Salt
Lake City, UT). This database includesmedical and pharmacy
claims, demographic data, and limited laboratory results for
more than 86 million members from over 40 healthcare plans.
Clinical and economic outcomes were compared between
individuals who had converted from administering glargine
via vial-and-syringe to the pen device (Switchers) and pa-
tients who continued to use vial-and-syringe administration
(Continuers).
Study design
Retrospective data were evaluated for adults diagnosed
with T2DM included in the IMPACT database during pre-
specified dates (between July 2006 and December 2010).
Eligible participants were to have had at least one inpatient
or two outpatient physician visits dated ‡ 30 days apart with
a primary or secondary diagnosis of International Classifi-
cation of Diseases, 9th Revision, Clinical Modification (ICD-
9-CM) code 250.x0 or 250.x2. In addition, participants were
required to have received at least two prescriptions for an
insulin glargine vial (GLA-V) between July 2006 and De-
cember 2010.
Eligible participants were divided into Switchers and
Continuers, based on insulin glargine use. Switchers were
identified as patients who filled at least one prescription for an
insulin glargine prefilled disposable pen (GLA-P), whereas
the Continuers never filled a prescription for GLA-P during
the study period. For the Switcher cohort, the index date was
defined as the date of the first prescription for GLA-P. To
allow a fair comparison on persistency and outcomes between
the Switcher and Continuer groups, a GLA-V claim was se-
lected randomly as the index date for the Continuer group,
starting from the third GLA-V claim during the study period.
For both cohorts, eligible participants were required to have
continuous healthcare plan enrollment with medical and
pharmacy benefits for at least 6 months before the index date
(defined as the baseline period) and 1 year after the index date
(defined as the follow-up period). Participants were also re-
quired to have had at least one GLA-V claim in each quarter
and at least one A1C test result during the baseline period.
Analyses and study end points
Various data were retrieved from the database, including
patient demographics, A1C values, comorbidities, and med-
ications. Each patient was assigned a Charlson Comorbidity
Index score, calculated by assigning disease severity weights
of 1–6 to 19 potential comorbid conditions.16 Baseline rapid-
acting insulin use was used to assign participants to a cate-
gory of no rapid-acting insulin, rapid-acting insulin vial, or
rapid-acting insulin pen. Baseline data were also collected for
hypoglycemia occurrence, healthcare costs and utilization,
and co-payments.
Outcome measures included treatment persistence and
adherence and clinical and economic outcomes. Treatment
persistence with insulin therapy is difficult to measure be-
cause of its nonfixed dosing. In previously published stud-
ies, an empirical approach was used to estimate insulin
treatment persistence using twomeasures: (1) 1-year follow-
up treatment persistence as dichotomous measures and (2)
treatment persistence days within 1-year follow-up as con-
tinuous measures.15,17–19 During the 1-year follow-up from
index date, patients were considered persistent with the
treatment if they remained on glargine therapy without
discontinuation or switching. Study medication was con-
sidered to have been discontinued if the prescription was
not refilled within the expected time of medication cover-
age, defined as the 90th percentile of the time, stratified by
the metric quantity supplied between first and second fills
among patients with at least one refill.15 The parameter
treatment persistence days was defined as number of days
from the index date until the treatment discontinuation/
switching date. Sensitivity analyses were also conducted
using the 75th and 95th percentiles of the time. Adherence to
insulin therapy was assessed as the adjusted medication
possession ratio (MPR), which takes into account the dif-
ferences in insulin device package size, during the 1-year
follow-up.20 Insulin package sizes may vary in volume
(10mL for vial, 5 · 3mL for pen, etc.). As the total volume
per package for pens is typically 50% larger than for vials,
this will result in longer average times between refills for
pen users (and vice versa), while the days’ supply infor-
mation recorded in the pharmacy claims may be similar
across pen and vial users. To correct for the difference in
refill times, the MPR was adjusted as follows: with the tra-
ditional MPR defined as the total day’s supply of all filled
study drug prescriptions in the analysis period divided by
the number of days in the analysis period, the adjusted
MPR for the pen group was calculated as the (traditional
MPR) · (average days between prescription refills for
patients using a pen/average days of supply for patients
using a pen). For the vial-and-syringe group, (traditional
MPR) · (average days between prescription refills for pa-
tients using vials/average days of supply for patients using
vial-and-syringe) was used.
Clinical outcomes included 1-year change in A1C from
baseline, hypoglycemia, and daily average consumption
(DACON) of insulin glargine. Hypoglycemiawas defined as a
healthcare encounter (outpatient, inpatient, or emergency
room [ER] visit) with a primary or secondary ICD-9-CM di-
agnosis code for hypoglycemia (ICD-9-CM code 250.8 for
diabetes with other specified manifestations, 251.0 for hypo-
glycemic coma, 251.1 for other specified hypoglycemia, or
251.2 for hypoglycemia, unspecified).21 The setting of the
hypoglycemic event (outpatient, ER, or hospital) was used as
proxy for severity of the event. Hypoglycemia was assessed
by both the prevalence rate of hypoglycemia-related events
(defined as the percentage of patients with at least one
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hypoglycemia-related event occurring during the 1-year
follow-up period) and the rate of hypoglycemic events (de-
fined as the number of new cases of hypoglycemia-related
events per 100 patients per year). DACON was calculated as
the total number of units dispensed before the last refill di-
vided by the total number of days between initiation and the
last refill during the 1-year follow-up period.
Economic outcomes included healthcare utilization and
cost. Healthcare utilizations were based on the number of
hospitalizations, ER and office visits, and inpatient days. All-
cause and diabetes-related health care costs in the follow-up
period were calculated for inpatient, outpatient, ER, pre-
scription, and total costs. Diabetes supply costs were also
calculated. Diabetes-related healthcare resource utilization
included claims with a primary or secondary diagnosis of
diabetes (ICD-9-CM of 250.xx). Diabetes-related healthcare
costs included costs from medical claims with a primary or
secondary diagnosis of diabetes (ICD-9-CM of 250.xx), anti-
diabetes medications, glucose meters, and test strips.
Statistical analyses
Before we undertook multivariate analyses comparing
the outcomes of treatment in the Switcher and Continuer
cohorts, patients from each cohort were matched using
propensity score matching at a 1:1 ratio to control for con-
founders.22 A patient from one cohort can only be matched
to a patient from the other cohort if their propensity
scores—fitted values of the probability of being a member
of the overall cohort—are within – 0.01 units of one another.
Patients who cannot be matched will be dropped from the
analysis. Patients in the Switcher and Continuer cohorts
were matched by the following baseline characteristics: age,
baseline A1C, co-payment, initial year, healthcare plan
type, geographic region, participation in diabetes education
programs, baseline DACON, baseline and adjusted MPR,
Charlson Comorbidity Index score, number of endocrinol-
ogist visits, any endocrinologist visits, number of oral an-
tidiabetes drug types (metformin, thiazolidinediones,
sulfonylureas, a-glucosidase inhibitors, and dipeptidyl
peptidase-4 inhibitors), diuretics, use of sulfonylureas, any
office visit, hypertension, and diabetes supply cost. Among
matched patients, baseline characteristics and clinical and
economic outcomes were summarized and compared, with
P values provided by Student’s t tests for continuous vari-
ables or v2 tests for categorical variables. Time to discon-
tinuation was analyzed using Kaplan–Meier analysis. Cox
regression was used to estimate the impact of switching to
pen versus continuing vial-and-syringe delivery on time to
treatment discontinuation of glargine.
Results
In total, 3,893 eligible patient records were identified from
the database: 665 patients were included in the Switcher
cohort, and 3,228 patients were included in the Continuer
cohort. After propensity score matching, 603 patients in the
Switcher cohort were matched with an equivalent number
of patients in the Continuer cohort. The remaining 52 pa-
tients in the Switcher cohort could not be so matched and
were excluded from the analysis, as were the remaining
unmatched patients in the Continuer cohort. Baseline
characteristics of the matched cohorts are shown in Table 1.
Table 1. Baseline Patient Characteristics
of the Matched Switcher and Continuer Cohorts
Characteristic
Pen switchers
(n = 603)
Vial continuers
(n = 603)
P
valuea
Mean (SD) age (years) 52.56 (11.53) 52.95 (11.52) 0.5587
Men [n (%)] 336 (55.7) 352 (58.4) 0.3520
A1C (%) [mean (SD)] 8.46 (1.85) 8.39 (1.73) 0.5141
CCI score [mean (SD)] 0.75 (1.47) 0.76 (1.48) 0.9378
Comorbidities [n (%)]
Hyperlipidemia 421 (69.8) 432 (71.6) 0.4863
Hypertension 387 (64.2) 388 (64.3) 0.9521
Retinopathy 101 (16.8) 107 (17.7) 0.6474
Neuropathy 99 (16.4) 83 (13.8) 0.1981
Mental illness 84 (13.9) 88 (14.6) 0.7419
Chronic pulmonary
disease
55 (9.1) 58 (9.6) 0.7669
Renal disease 57 (9.5) 45 (7.5) 0.2143
Nephropathy 43 (7.1) 55 (9.1) 0.2060
Congestive heart
failure
46 (7.6) 39 (6.5) 0.4310
Peripheral vascular
disease
45 (7.5) 34 (5.6) 0.2005
Oral antidiabetic drugs [n (%)]
Metformin 240 (39.8) 241 (40.0) 0.9531
Sulfonylureas 132 (21.9) 130 (21.6) 0.8889
Thiazolidinediones 112 (18.6) 114 (18.9) 0.8827
Dipeptidyl
peptidase-4
inhibitors
49 (8.1) 46 (7.6) 0.7485
Glucagon-like
peptide-1 agonists
45 (7.5) 38 (6.3) 0.4259
Meglitinides 14 (2.3) 19 (3.2) 0.3775
RAI indicator [n (%)]
No RAI 264 (43.8) 261 (43.3) 0.8617
RAI vial 111 (18.4) 116 (19.2) 0.7126
RAI pen 228 (37.8) 226 (37.5) 0.9054
Insulin DACON (units)
[mean (SD)]
40.60 (23.64) 41.32 (23.18) 0.5928
Mean (SD) MPR 0.71 (0.20) 0.71 (0.19) 0.9029
Mean (SD) adjusted
MPR
0.86 (0.18) 0.86 (0.17) 0.9234
Hypoglycemia rates [n (%)]
Any hypoglycemia 44 (7.3) 42 (7.0) 0.8229
Any inpatient/ER
hypoglycaemia
24 (4.0) 15 (2.5) 0.1429
Mean (SD) costs ($)
All-cause cost (total) 9,849 (17,969) 9,589 (14,923) 0.7853
Inpatient cost 2,764 (13,011) 2,527 (10,854) 0.7313
Outpatient cost 3,635 (7,326) 3,606 (6,849) 0.9419
ER cost 352 (1,222) 270 (911) 0.1887
Prescription cost 3,098 (2,593) 3,187 (3,113) 0.5885
Diabetes-related
cost (total)
4,071 (7,191) 3,921 (5,966) 0.6945
Inpatient cost 1,155 (5,739) 1,164 (5,219) 0.9778
Outpatient cost 1,213 (3,354) 1,039 (2,065) 0.2780
ER cost 157 (726) 144 (612) 0.7277
Prescription cost 1,290 (909) 1,318 (950) 0.5965
Diabetes supply
cost
256 (292) 257 (294) 0.9549
The baseline period was defined as 6 months prior to the index date.
aP values provided by Student’s t tests for continuous variables or
v2 tests for categorical variables.
A1C, glycosylated hemoglobin A1C; CCI, Charlson Comorbidity
Index; DACON, daily average consumption; ER, emergency room;
MPR, medication possession ratio; RAI, rapid-acting insulin.
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All baseline characteristics were comparable for the two
cohorts, with the matched sample used for all subsequent
analyses.
Persistence and adherence
During the 1-year follow-up period, patients in the
Switcher cohort had significantly higher persistence than
patients in the Continuer cohort (65.3% vs. 49.8%; P < 0.0001).
This finding was confirmed by sensitivity analyses conducted
at the 75th (39.6% vs. 26.4%, P < 0.0001) and 95th (78.4% vs.
61.4%, P < 0.0001) percentiles. The number of treatment per-
sistence days was also significantly higher for patients in the
Switcher cohort (299.9 – 94.9 days) compared with the Con-
tinuer cohort (264.0 – 113.6 days) (P < 0.0001). Based on ad-
justed MPR, patients in the Switcher cohort were also
significantly more adherent than those in the Continuer co-
hort (0.79 vs. 0.76; P = 0.0173).
Kaplan–Meier analysis showed that Continuers were more
likely to discontinue earlier than Switchers during the 1-year
follow-up (log-rank test P < 0.0001; Fig. 1). These results were
confirmed byCox regression analysis; after adjusting for other
factors, Switchers were less likely to discontinue early than
Continuers (hazard ratio of 0.544; P< 0.0001).
Clinical outcomes
DACONof insulin did not differ for patients in the Switcher
(42.8 units) and Continuer (42.3 units) cohorts (P = 0.7757).
A1C values were available for 350 matched Switcher and
Continuer patients. The respective change in A1C from
baseline was similar for Switchers and Continuers (- 0.04%
and - 0.24%, respectively; P = 0.0899). A similar percentage of
patients in the Switcher and Continuer cohorts had a follow-
up A1C value of < 7.0% (24.9% vs. 22.3%; P = 0.4229).
Hypoglycemia incidence rates were also similar for the two
cohorts: any hypoglycemic event occurred in 10.8% of
Switchers and 11.6% of Continuers (P = 0.6479), with a hy-
poglycemia-related hospitalization or ER visit reported for
3.8% of Switchers and 4.6% of Continuers (P= 0.4743). The
average number of hypoglycemic events per 100 patient-years
was 43 in Switchers and 31 in Continuers (P = 0.3648), and the
average number of hypoglycemia-related hospitalizations or
ER visits per 100 patient-years was six for both Switchers and
Continuers (P = 0.8702).
Healthcare utilization and costs
Overall and diabetes-related healthcare utilizations during
the 1-year follow-up period are summarized in Table 2. There
were no statistical differences in healthcare utilization be-
tween the two cohorts.
The overall and diabetes-related healthcare costs in-
curred during the 1-year follow-up period are shown in
Table 2. Switchers and Continuers had similar overall
($20,870– 30,534 vs. $20,747 – 29,803; P = 0.9434) and diabetes-
related ($8,333 – 10,344 vs. $8,494– 11,284; P = 0.7972) total
costs. As expected, diabetes-related prescription costs were
significantly higher for Switchers compared with Continuers
($3,393– 2,351 vs. $2,889– 2,035; P = 0.0001). However, this
higher prescription cost was offset by lower overall and dia-
betes-related outpatient and inpatient costs among Switchers
than Continuers.
Discussion
This retrospective study of the IMPACT database showed
significant improvements over a 1-year follow-up period in
treatment persistence and adherence among patients who
were treated with insulin glargine for T2DM and who swit-
ched from vial-and-syringe to prefilled disposable pen ad-
ministration compared with patients who continued to use
vial-and-syringe delivery. Clinical outcomes were similar
between the two groups, which is similar to a previously
FIG. 1. Kaplan–Meier curve of time to discontinuation of all glargine use for the matched Switcher and Continuer cohorts.
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reported randomized comparative trial with pen versus vial-
and-syringe for insulin aspart administration.8 Furthermore,
improved treatment persistence and adherence were
achieved without a significant increase in healthcare utiliza-
tion or total costs. For healthcare payers, such as health in-
surance companies, these findings imply that disposable
pen devices for insulin administration may be a more cost-
effective option than the traditional vial-and-syringe, in that
themarginal benefits of these devices outweigh theirmarginal
costs.
In an observational study conducted in patients with type 1
or 2 diabetes who had recently switched to or started insulin
treatment using insulin glargine by pen, at least 95% of pa-
tients rated pen use as either good or excellent for ease of use,
learning to use, and selecting and reading the dose. The study
data suggest that, despite major changes in therapy, the new
treatment and administration methods were well accepted by
patients.23 Intuitively, it would follow that changes in patient
perception in these areas may lead to improvements in per-
sistence and adherence. Data from the current study support
previously published studies showing improved adherence
and persistence when initiating insulin treatment using a
pen delivery system rather than vial-and-syringe15,17,24 or
after switching from vial-and-syringe administration to pen
delivery.11,12 Although some studies have reported a reduc-
tion in the risk of hypoglycemia following switching to pen
delivery,1,5,11,12 glycemic control was similar between patients
using pen and vial-and-syringe delivery systems in the cur-
rent study.
Previously published data have shown that the use of
pensmay contribute to improved glycemic control.15 The use
of pen devices may indirectly contribute to improved A1C
levels by increasing patient adherence and satisfaction14 or
by improving accuracy of administration.15,25 Improved
glycemic control, however, was not observed after switching
to pen administration in the current study. Furthermore, in
contrast to other studies,11,12 the current study did not ob-
serve any reduction in the incidence of hypoglycemia and
associated healthcare utilizations among patients who
switched to a pen device compared with those continuing
with a vial-and-syringe method. Cobden et al.12 reported a
significantly decreased risk of hypoglycemia-attributable ER
visits (odds ratio [OR] 0.36, 95% confidence interval [CI]
0.16–0.84) and physician visits (OR 0.39, 95% CI 0.20–0.77) if
patients switched from vial-and-syringe to pen device us-
age for the delivery of insulin. Lee et al.11 likewise reported
that the likelihood of experiencing a hypoglycemic event
was significantly reduced after patients had switched to
using a pen device for the delivery of insulin (OR 0.50, 95%
CI 0.37–0.67). This discrepancy may be due to the different
Table 2. Healthcare Costs and Utilizations of the Matched Switcher and Continuer Cohorts
at the End of the 1-Year Follow-Up Period
Utilization Pen switchers (n = 603) Vial continuers (n = 603) P valuea
Overall healthcare utilization
Any hospitalization [n (%)] 103 (17.1) 111 (18.4) 0.5465
Hospitalizations per patient [n (SD)] 0.27 (0.69) 0.29 (0.76) 0.6346
Hospitalization days [n (SD)] 2.05 (8.26) 2.09 (8.80) 0.9301
Any ER visit [n (%)] 215 (35.7) 187 (31.0) 0.0872
ER visits per patient [n (SD)] 0.85 (2.33) 0.87 (2.54) 0.8966
Any office visit [n (%)] 601 (99.7) 601 (99.7) 1.0000
Office visits per patient [n (SD)] 18.34 (17.36) 18.41 (17.18) 0.9376
Any endocrinologist visit [n (%)] 288 (47.8) 277 (45.9) 0.5256
Endocrinologist visits per patient [n (SD)] 1.59 (2.21) 1.59 (2.22) 0.9896
Diabetes-related healthcare utilization
Any hospitalization [n (%)] 93 (15.4) 100 (16.6) 0.5825
Hospitalizations per patient [n (SD)] 0.22 (0.61) 0.22 (0.57) 0.9608
Hospitalization days [n (SD)] 1.69 (7.47) 1.73 (8.25) 0.9185
Any ER visit [n (%)] 149 (24.7) 141 (23.4) 0.5899
ER visits per patient [n (SD)] 0.38 (0.86) 0.41 (1.07) 0.6158
Any office visit [n (%)] 597 (99.0) 591 (98.0) 0.1542
Office visits per patient [n (SD)] 8.01 (7.63) 7.91 (6.58) 0.8116
Mean (SD) overall healthcare costs ($)
Total cost 20,870 (30,534) 20,747 (29,803) 0.9434
Inpatient cost 5,276 (18,096) 5,515 (18,080) 0.8182
Outpatient cost 7,699 (16,958) 7,921 (16,114) 0.8160
ER cost 652 (2,359) 646 (1,867) 0.9646
Prescription cost 7,244 (5,674) 6,665 (6,038) 0.0863
Mean (SD) diabetes-related healthcare costs ($)
Total cost 8,333 (10,344) 8,494 (11,284) 0.7972
Inpatient cost 2,048 (8,213) 2,366 (7,670) 0.4876
Outpatient cost 2,068 (3,440) 2,380 (6,835) 0.3165
ER cost 271 (1,087) 311 (1,201) 0.5511
Prescription cost 3,393 (2,351) 2,889 (2,035) 0.0001
Diabetes supply cost 553 (632) 548 (592) 0.8943
aP values provided by Student’s t tests for continuous variables or v2tests for categorical variables.
ER, emergency room.
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study designs. Cobden et al.12 and Lee et al.11 used a simple
pre–post comparison approach in their articles, whereas the
current study used a more robust controlled cohort analysis
with propensity score matching. Instead of comparing with
the pre-switching period, the current study used amethod in
which the hypoglycemia rate for Switchers during the fol-
low-up period was compared with that in the Continuer
group. Both groups had low rates of hypoglycemia; there-
fore, the sample size may have been too small to detect sig-
nificant differences.
This study has several limitations. The IMPACT database
comprises claims submitted by healthcare providers to in-
surance companies for reimbursement on behalf of the em-
ployees of client companies and may be subject to coding
errors andmissing data. The population sample considered in
this retrospective analysis is based on a large convenience
sample, which by its nature is nonrandom and therefore may
be subject to bias, limiting the generalizability of the findings
to similar populations and treatments.24 Also, the use of
pharmacy claims data and patient medical histories to mea-
sure adherence and persistence may not provide sufficiently
detailed information to ensure that prescribed medications
are being appropriately used. In addition, as in any retro-
spective study, causality between treatment and differences in
outcomes cannot be established. Furthermore, our study is
limited to only 1 year of follow-up, and significant differences
may have been noted if longer follow-up had been used.
Considering that A1C is an important health outcome for
T2DM, another limitation of this analysis is the fact that A1C
data were only available for a proportion of patients (350 of
603). Finally, the use of pen devices has been shown to facil-
itate insulin administration in patients with visual impair-
ments or restricted manual dexterity—for example, elderly
patients.5,26,27 Our study did not compare outcomes among
patients based on age or visual impairments, although this
might be considered as a potentially important contributing
factor in subsequent studies.
In conclusion, this real-world study has shown that
switching from vial-and-syringe to a pen device for insulin
glargine administration resulted in increased treatment per-
sistence and adherence with similar clinical outcomes. De-
spite the higher diabetes-related prescription costs associated
with the switch to pen use, there was no increase in total
healthcare costs, suggesting that the switch to pen use is a
cost-effective option for improving insulin persistence and
adherence. These findings may assist with optimizing the
management of patients with T2DM.
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